Fig.4.
A) Quantitative analysis of the uptake of hydrophilic SPIO, free irinotecan, and SPIO@IR by flow cytometry; B) In vitro cytotoxicity of hydrophilic SPIO, free Irinotecan, and SPIO@IR; C) Annexin V-FITC FACS apoptosis analysis of HT-29 cancer cells after treatment with PBS, hydrophilic SPIO, free irinotecan, and SPIO@IR.